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Abstract
Background: To compare epidemiological data between recurrent cases after cure (RC), distinguishing relapse from
reinfection, after dropout (RD) and new cases (NC) in an ambulatory setting in a TB-endemic country.
Methods: Records of patients who started treatment for pulmonary TB between 2004 and 2010 in a TB clinic were
reviewed. Epidemiological data were analyzed. Spoligotyping and MIRU patterns were used to determine relapse or
reinfection in 13 RC available.
Results: Of the eligible group (1449), 1060 were NC (73.2%), among the recurrent cases, 203 (14%) were RC and
186 (12.8%) were RD. Of RC, 171 (84.2%) occurred later than 6 months after a previous episode, 13 had available
DNA, in 4 (30.7%) the disease was attributed to reinfection and in 9 (69.3%), to relapse. Comparing RC to NC, HIV
(p < 0.0001) was independent risk factor for RC. When RC and RD were compared, alcohol abuse (p = 0.001) and
treatment noncompliance (p = 0.006) were more frequent in RD.
Conclusions: HIV is the sole more important associated factor for RC. This finding points the need to improve the
approach to manage TB in order to decrease the chance for exposure especially in vulnerable people with
increased risk of developing disease and to improve DOTS strategy to deal with factors associated to treatment
noncompliance.
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Background
Although many studies have been done about recur-
rence of tuberculosis (TB) following completion of treat-
ment it is still a huge problem for public health in high
burden countries, where no special attention is being
given to this subject [1]. Treatments of recurrent epi-
sodes are often associated with drug resistance and low
cure rates. The incidence and risk factors for recurrence,
as well as the contribution of relapse or reinfection is
being searched by several studies with different results
[2-9]. Recurrence rates depend largely on TB incidence
and HIV prevalence [3,4]. In high incidence areas for
TB, people who have been treated successfully are at
higher risk of developing TB from reinfection than the
general population and HIV are at more risk of reinfec-
tion than non HIV [9-11].
In 2010, the Brazilian Ministry of Health made changes
in TB treatment, adding a fourth drug to the basic regi-
men because of increasing resistance and imposed direct
observed treatment for multidrug resistant tuberculosis
(MDRTB) as a rule to provide the drugs to ensure adhe-
sion to treatment as an effort to decrease new cases and
recurrence [12].
This study aimed to investigate recurrence after cure
(RC), to distinguish relapse from reinfection and compare
to new cases (NC) and recurrence after dropout (RD) in
an ambulatory setting in a high burden area for TB and
HIV in Brazil, describing epidemiological characteristics
of these groups in order to bring new strategies to control
recurrence, meaning primary and secondary preventive
therapy, implementation of infection control measures in
clinical and community settings and special care to vul-
nerable groups.
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The study was conducted in a reference Center for TB,
placed at Hospital Sanatório Partenon in Porto Alegre
city, Rio Grande do Sul, Brazil. It covers the east side of
the city, counting about 180.000 inhabitants (12% of
Porto Alegre population). The incidence of cases was on
average 104.6 per 100.000 population per year (2004-
2010). In the study area, the prevalence of HIV infection
among new patients was approximately 23% [13].
Ethics compliance
This study was approved by the ethical committee of
Fundação Estadual de Produção e Pesquisa em Saúde –
FEPPS/SES/RS (protocol number 02/2010).
Study population and follow-up
All adult cases starting treatment for pulmonary tuber-
culosis confirmed by baciloscopy and/or culture between
2004 and 2010 were eligible for this retrospective ana-
lysis. New cases (NC), recurrence after cure (RC) or re-
currence after dropout (RD) were analyzed for HIV
status, and other epidemiological factors such as: sex,
age, alcohol abuse, and drugs, smoking and treatment
compliance. If recurrence after cure, period between the
two episodes and cultures done in the first and second
episode were also analyzed. All retreatment patients after
cure with a positive culture in the first and second epi-
sodes available were identified for relapse or reinfection
by molecular techniques.
Definitions
A TB case was defined as pulmonary tuberculosis con-
firmed by baciloscopy and/or culture with radiological
and clinical findings suggestive of TB. Recurrence of TB
was defined as a second episode of TB occurring after a
first episode had been considered cured.
Disease attributable to reinfection was defined as a re-
current disease episode with a different M. tuberculosis
strain. Relapse was defined as a recurrent disease epi-
sode with the same M. tuberculosis strain found in the
previous episode, assuming that reinfection with the
same strain is not expected to be significant because
strain diversity in this community is high [14-16]. The
same definition was proposed by others [1,4,7,9] New
case was defined as a case without any previous treat-
ment. Recurrence was considered any time after end of
treatment of the previous episode. A period less than 3
months after the end of the first treatment and longer
than 60 months was excluded for epidemiological statis-
tics inferring shorten period could be failure of treat-
ment in most of the cases, and a period longer than five
years as a new case. World Health Organization defini-
tions were used to determine treatment outcome. A
patient was considered cured when initially smear-
positive and who was smear-negative in the last month
of treatment and on at least one previous occasion.
Laboratory methods
Susceptibility test and DNA extraction
The isolates were cultured in Löwenstein Jensen solid
medium. The drug susceptibility testing was performed
according to the proportion method described by Canetti
et al. [17]. Chromosomal DNA extraction was performed
using the cetyltrimethylammonium bromide (CTAB)
method as described by van Soolingen et al. [18].
Genotyping analysis
Spoligotyping was performed as described by Kamerbeek
et al. with a commercial kit (Ocimum Biosolutions BV,
India) and the results were compared to a public database
available at: http://www.pasteur-guadeloupe.fr:8081/SIT-
VIT_ONLINE [19,20]. MIRU-VNTR was carried out by
Genoscreen® using the commercial 24-loci format. If
MIRU-VNTR has at least one locus of difference it was
considered as different strains.
Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS Inc., Chicago, IL). The groups RC, RD and NC
were compared by Chi-square, t-test. Logistic regression
analysis was made in the cases where bivariate analysis
showed significative differences. Statistical significance
was considered if p <0.05 with 95% confidence intervals.
To analyze possible confounders variables, multivariable
analysis was performed.
Results
A total of 1522 adult patients started treatment for pul-
monary TB between 2004 and 2010. Patients starting
treatment after failure were excluded (73/4.6%). In the
eligible group (1449), there were 1060 new cases (NC)
(73.2%). Among the recurrent cases, 203 (14%) were RC
and 186 (12.8%) were considered RD (Figure 1).
HIV positive status of the 3 groups NC, RC and RD
were respectively 22.5, 37.7 and 43.3%. These groups
were further compared about sex, age, smoking, alcohol
abuse, drugs, and treatment compliance (Table 1).
Comparing RC to NC, there were statistics differences
in HIV status. These results indicate that HIV infection
is an independent risk factor for recurrence of TB after
cure [OR = 2.15 (1.55-2.97); p < 0.0001)]. Most of the 203
recurrences occurred later than 6 months after the end of
the treatment of a previous episode 84.2% (n = 171/203).
When considering only patients with a period between ep-
isodes less than 3 months (90 days) or higher than 60
months (1800 days); 121 of 203 recurrences; 97 (80.16%)
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occurred later than 6 months after the end of the treat-
ment of a previous episode.
When RC and RD were compared, HIV status was not
different in these groups. In the other hand, alcohol
abuse and treatment noncompliance were statistically
more frequent in those that dropped treatment [OR =
2.60 (1.46-4.65); p = 0.001)] and [OR = 2.15 (1.24-3.73);
p = 0.006)] respectively.
Of the 203 recurrent TB cases, 24 had cultures done
in the first and second episodes, but only 13 strains were
available to culture for further DNA extraction. Spoligo-
typing and MIRU-VNTR were performed on available
strains to differentiate whether the disease is due to re-
infection or relapse. According to molecular techniques,
in 4 (30.7%) patients the disease was attributed to re-
infection and in 9 (69.3%), to relapse.
In the reinfection patients, according to MIRU-VNTR
technique, there was an interval of 6 months or more
between the first and second episode. In two of them,
strains were isoniazid (INH) and rifampicin (RMP) re-
sistant in both episodes. One patient had a INH resistant
•
•
Figure 1 The flow chart of tuberculosis patient selection.
Table 1 Epidemiological and clinical characteristics of TB
patients in the study period
Total (n = 1449) NC (%) RC (%) RD (%)








Sex Male 1060/203/186 67.2 63.1 75.3
HIV-positivity 1034/199/180 22.5a 37.7a 43.3
Alcohol abuse 965/171/152 35.5 35.7b 60.5b
Drug abuse 911/160/145 29.3 31.9 55.9
Smoke 971/172/153 63.4 65.7 73.9
Treatment
noncompliance
940/170/163 28.5 34.7c 60.7c
Age years,
median
1060/203/186 37 ± 13.9 39.6 ± 12.39 36.4 ± 10.7
NC = New Cases.
RC = Recurrence after cure.
RD = Recurrence after dropout.
aOR = 2.15 (1.55-2.97); p < 0.0001.
bOR = 2.60 (1.46-4.65); p = 0.001.
cOR = 2.15 (1.24-3.73); p = 0.006.
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episode, followed by a susceptible strain 700 days later
(patient 7 in Additional file 1: Table S1). Patient 11 had
two susceptible strains in both episodes. Three patients
were HIV positive and one negative (Additional file 1:
Table S1).
In 9 (69.3%) cases the disease was attributed to relapse
due to identical MIRU-VNTR profile. Among them,
there were six patients that relapsed 6 months or more
after the first episode. In this group, 6 cases were sus-
ceptible to all tested drugs, 2 cases were RMP and INH
resistant and one was RMP resistant. Two patients were
HIV positive and seven negative. No statistical differ-
ences between the two groups (relapse and reinfection)
were found.
Among 26 spoligotyping performed, LAM and T fam-
ily were the most common, 10 (38.5%). and 6 (23%)
strains respectively.
Discussion
In a previous study at the same city, recurrence of tuber-
culosis was estimated as 4.3% between 1989 and 1994
(0.55/100 person-years) [7]. Now, the high incidence of
recurrence (26.8% of patients, n = 389) in the study
period shows that TB is far from being controlled in this
area and evidences the need to characterize this popula-
tion. Since then, the incidence of HIV and TB had in-
creased, achieving the second position in the unwanted
ranking of brazilian capitals with one of the highest TB
(104.6/100000 habitants) and TB/HIV (1/3 of them) in-
cidence. Korenromp et al. found, in a study carried out
in sub-Saharan Africa, rates of TB recurrence were up to
20/100 person years [21]. In a low incidence area,
Nashville-Tennessee-USA, from 1431 reported TB cases,
20 (1.4%) cases recurred in the studied period [22]. It
clearly shows the quality of TB control programs in
these areas, as recurrence rates can be used to assess the
effectiveness of TB control programs. In high TB inci-
dence areas, recurrences are likely due to reinfection, re-
lated to the maintenance of infection source. However,
in low incidence areas, when infection control is ad-
equate, recurrences are likely due to relapse.
In thirteen publications from 1993 to 2001, reviewed
by Lambert et al. [1], there was not a concordance about
a standard in terms of timing to characterize recurrence.
In two recently published reports, Millet et al. defined at
least twelve months between two positive culture and
for Luzze et al., it was considered any time after the end
of the previous treatment [8,9]. For epidemiological stat-
istical proposal, to compare time between episodes it
was considered from 3 months to five years, inferring
shorten period could be failure of treatment in most of
the cases, and a period longer than five years as a new case
[7]. Nunn et al. reported 78% of 574 recurrences by re-
lapses, occurred within 6 months of stopping treatment
and 525 recurrences by reinfection (91%) within 12
months [23]. Recurrence due to relapse seems to occur
closer to the time of cure [24]. In a large study made in a
sub-Saharan TB-endemic country the median duration to
TB recurrence was 9.9 months, in agreement with earlier
African studies where 90% of clinical relapses occurred
within 12 months after completing treatment [8,25,26]. In
the same study time to reinfection was longer than to re-
lapse (20.1 vs. 8.1 months p = 0.07) in HIV-positive pa-
tients [8]. In our study HIV positive patients had a
longer time between episodes than HIV negative pa-
tients (p = 0.049) suggesting that reinfection may be
more implicated than relapse in HIV positive and re-
lapse may be more implicated in HIV negative. HIV
positive patients attend more frequently the public
health system, probably being more exposed to a new
infection and are more susceptible to disease when in-
fected. According Pettit et al. the higher rate of reinfec-
tion among HIV infected patients may be related to
increase in exposure in high incidence areas and subse-
quent increased risk for disease progression [22]. The
high number of recurrence in our study and the time
between episodes suggest reinfection playing most of
the cases as it is expected in a high burden area
[1,4,7,9], with a high strain diversity circulating [14-16].
Comparing RC to NC, HIV infection was independent
risk factor for recurrence of TB after cure. Millet et al.
reported more risk of TB recurrence in HIV positive pa-
tients [9]. Sonnenberg et al., Panjabi et al. and Pettit et al.
report HIV infection as factor independently associated
with recurrence [22,27,28]. Studies involving HIV positive
patients have reported higher recurrence rates [9,22,29].
In our study 37.7% of recurrent patients after cure were
HIV positive.
When RC and RD were compared, HIV status was not
different in these groups. In the other hand, alcohol
abuse and treatment noncompliance were statistic more
frequent in those that dropped treatment than in RC
group. In another study, the noncompliance was higher
in alcohol abuse cases (20.9% vs. 9.9%; p = 0.01) [7].
Many studies were done to identify risk factors associ-
ated with TB treatment default. Alcohol use or alcohol
abuse has been frequently reported as a risk factor for
default [30-33].
As sputum culture in Brazil is not available for each pa-
tient starting treatment, only in few it was possible to ob-
tain sputum in the first episode and in the recurrence of
the disease for genotyping analysis [12]. Among the thirteen
patients analyzed, in 4 (30.7%) patients the disease was at-
tributed to reinfection and in 9 (69.3%), to relapse. There is
no statistical difference among reinfection and relapse for
epidemiological characteristics including HIV status.
The LAM family was the most frequent pattern in-
volved in relapse, which is expected as this family was
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the most common in the study and it is very common in
the study area as well as in Brazil [14-16]. The T family,
the second most common family, is also, a very common
profile causing TB disease in the South Brazil [14-16].
The study had no correlation among spoligopatterns
families and resistance profile.
Despite no statistically difference among HIV status in
the relapse group, probably due to the few number ana-
lyzed, there was a trend to an increase of relapse in HIV
negative. Our findings are consistent with a study per-
formed in an area of medium to high TB incidence,
when HIV-negative patients are predominantly affected
by relapse, while HIV positive patients are at risk of both
relapse and reinfection [29,34,35]. The median time to
TB relapse was 550 days. A very similar number reported
was found by Pettit et al., when relapse was 412 days, des-
pite this study was performed in low TB incidence area,
approximately 5/100 000 against Porto Alegre area which
TB incidence is approximately 160/100 000 [22].
Conclusions
Considering the high incidence of recurrence, the period
longer than 6 months after the previous episode suggests
reinfection as a major cause for recurrence in a high set-
ting of TB and HIV. HIV is the sole more important as-
sociated factor for recurrence after cure and alcohol
abuse for treatment dropout. These finding points to the
need for another approach to manage TB in order to de-
crease the chance for exposure especially in vulnerable
people with increased risk of developing disease and to
improve DOTS strategy to deal with factors associated
to treatment noncompliance including psychological and
social worker assistance.
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